New Partnership to Provide Bioanalytical and DMPK Services
Concept Life Sciences (“Concept”), the integrated drug discovery, development and analytical services company, and Alderley Analytical, the GLP/GCP compliant, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.
Under the terms of the agreement, Concept will gain access to Alderley Analytical’s significant expertise in bioanalysis, and Alderley Analytical will benefit from Concept’s deep understanding of synthetic, organic and medicinal chemistry, biology, toxicology, and analytical services. The combined offering will give clients of both companies, including biotech, pharma and agrochemicals companies, access to industry-leading assay development services for quantification of new molecules in a biological matrix, using the most sensitive instrumentation available.
Michael Fort, Executive Chairman, Concept Life Sciences, commented: “The team at Alderley Analytical has built an impressive reputation for delivery of the highest quality GLP/GCP bioanalytical services. Combining this offering with our Group’s expertise, including the recent additions of translational biology and large molecule research, brings benefits to the widest group of life sciences clients.”
This article has been republished from materials provided by Concept Life Sciences. Note: material may have been edited for length and content. For further information, please contact the cited source.
Microorganisms often assemble natural products similar to industrial assembly lines. Certain enzymes, non-ribosomal peptide synthetases (NRPS) play a key role in this process. Biotechnologists have now discovered how these enzymes interact with each other, bringing them one step closer to their goal of engineering peptide natural products.READ MORE
In new studies a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia. Unlike its experimental predecessors, the new drug does not appear to cause systemic side effects or overcorrect with excessive blood oxygenation, which can itself be toxic. Instead, the new drug delivers its precious oxygen cargo only to the tissues that need it most.READ MORE